CN110430871A - 可压缩性改善的粒度受控的吡非尼酮的药物组合物及其制备方法 - Google Patents
可压缩性改善的粒度受控的吡非尼酮的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN110430871A CN110430871A CN201880018876.5A CN201880018876A CN110430871A CN 110430871 A CN110430871 A CN 110430871A CN 201880018876 A CN201880018876 A CN 201880018876A CN 110430871 A CN110430871 A CN 110430871A
- Authority
- CN
- China
- Prior art keywords
- pirfenidone
- composition
- tablet
- preparation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0027228 | 2017-03-02 | ||
KR1020170027228A KR20180100869A (ko) | 2017-03-02 | 2017-03-02 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
PCT/KR2018/002484 WO2018160011A1 (ko) | 2017-03-02 | 2018-02-28 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110430871A true CN110430871A (zh) | 2019-11-08 |
Family
ID=63370533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880018876.5A Pending CN110430871A (zh) | 2017-03-02 | 2018-02-28 | 可压缩性改善的粒度受控的吡非尼酮的药物组合物及其制备方法 |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP2020509053A (ja) |
KR (1) | KR20180100869A (ja) |
CN (1) | CN110430871A (ja) |
WO (1) | WO2018160011A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102199415B1 (ko) * | 2019-02-18 | 2021-01-06 | 충북대학교 산학협력단 | 중합체 및 채널링제를 포함하는 피르페니돈 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제 |
US20230158004A1 (en) * | 2020-04-22 | 2023-05-25 | Yungjin Pharm. Co., Ltd. | Enteric-coated preparation comprising pirfenidone having improved safety and stability, and method for preparing same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
CN102552203A (zh) * | 2010-12-21 | 2012-07-11 | 北京德众万全医药科技有限公司 | 一种吡非尼酮片及其制备方法 |
CN102846555A (zh) * | 2012-04-09 | 2013-01-02 | 珠海亿邦制药股份有限公司 | 一种以吡非尼酮为活性成分的固体制剂及其应用 |
CN102846569A (zh) * | 2012-09-06 | 2013-01-02 | 北京万全德众医药生物技术有限公司 | 一种含吡非尼酮的药物组合物及其制备方法 |
CN103271886A (zh) * | 2013-05-29 | 2013-09-04 | 南京正大天晴制药有限公司 | 一种吡非尼酮片剂及其制备方法 |
CN103957892A (zh) * | 2011-07-19 | 2014-07-30 | 细胞治疗技术合伙股份有限公司 | 以缓释片剂形式制备含有吡非尼酮的药物组合物的方法及其在人慢性肾功能衰竭、乳房包膜挛缩和肝纤维化的复原中的应用 |
CN106176641A (zh) * | 2015-02-05 | 2016-12-07 | 保宁制药株式会社 | 片剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
-
2017
- 2017-03-02 KR KR1020170027228A patent/KR20180100869A/ko active IP Right Grant
-
2018
- 2018-02-28 JP JP2019547670A patent/JP2020509053A/ja active Pending
- 2018-02-28 CN CN201880018876.5A patent/CN110430871A/zh active Pending
- 2018-02-28 WO PCT/KR2018/002484 patent/WO2018160011A1/ko active Application Filing
-
2021
- 2021-12-27 JP JP2021213391A patent/JP2022031527A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
CN102552203A (zh) * | 2010-12-21 | 2012-07-11 | 北京德众万全医药科技有限公司 | 一种吡非尼酮片及其制备方法 |
CN103957892A (zh) * | 2011-07-19 | 2014-07-30 | 细胞治疗技术合伙股份有限公司 | 以缓释片剂形式制备含有吡非尼酮的药物组合物的方法及其在人慢性肾功能衰竭、乳房包膜挛缩和肝纤维化的复原中的应用 |
CN102846555A (zh) * | 2012-04-09 | 2013-01-02 | 珠海亿邦制药股份有限公司 | 一种以吡非尼酮为活性成分的固体制剂及其应用 |
CN102846569A (zh) * | 2012-09-06 | 2013-01-02 | 北京万全德众医药生物技术有限公司 | 一种含吡非尼酮的药物组合物及其制备方法 |
CN103271886A (zh) * | 2013-05-29 | 2013-09-04 | 南京正大天晴制药有限公司 | 一种吡非尼酮片剂及其制备方法 |
CN106176641A (zh) * | 2015-02-05 | 2016-12-07 | 保宁制药株式会社 | 片剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
庄越等: "《实用药物制剂技术》", 31 January 1999, 人民卫生出版社 * |
韦超等: "《药剂学》", 31 August 2012, 河南科学技术出版社 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018160011A1 (ko) | 2018-09-07 |
JP2020509053A (ja) | 2020-03-26 |
JP2022031527A (ja) | 2022-02-18 |
KR20180100869A (ko) | 2018-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7361676B2 (en) | Solid preparation containing single crystal form | |
EP1049467B1 (en) | Celecoxib compositions | |
EP1884242A1 (en) | Pharmaceutical composition | |
JP5401327B2 (ja) | 溶出性の改善された錠剤 | |
EP3437646A1 (en) | Oral preparation having exceptional elutability | |
TWI700100B (zh) | 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物及其製備方法 | |
TWI727935B (zh) | 含有細胞週期蛋白抑制劑固體分散體的醫藥組成物及其製備方法 | |
CN106389360A (zh) | 盐酸达泊西汀直压片及其制备方法 | |
EP3661508B1 (en) | Manufacturing method of oral dosage form containing berberine, oral dosage form containing berberine and use thereof | |
CN105935358B (zh) | 一种沙库比曲缬沙坦缓释剂及其制备方法 | |
WO1999059552A1 (fr) | Preparations a liberation controlee | |
CA2761212A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing | |
CN110430871A (zh) | 可压缩性改善的粒度受控的吡非尼酮的药物组合物及其制备方法 | |
WO2006123213A1 (en) | Modified release formulations of gliclazide | |
KR20140022002A (ko) | 고형 의약 조성물 | |
EP2696857A1 (en) | Pharmaceutical composition comprising bosentan | |
KR20190110771A (ko) | 데페라시록스를 함유하는 소형 분산성 정제 | |
KR101774690B1 (ko) | 라록시펜과 비타민 d를 포함하는 복합제제 | |
JP4756153B2 (ja) | 低成分含量の錠剤の製造方法 | |
CA2987850A1 (en) | Alogliptin formulation | |
JP2006176496A (ja) | 固形剤およびその製造方法 | |
CN115212206B (zh) | 一种含吡非尼酮的药物组合物及其制备方法 | |
US20080194560A1 (en) | Disintegration promoters in solid dose wet granulation formulations | |
EP4438036A1 (en) | Solid pharmaceutical composition | |
Pimple et al. | Formulation and evaluation of immediate release tablets of s (-) metoprolol succinate using roller compaction approach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |